A Phase 1 Trial of Fuzuloparib in Combination with Apatinib for Advanced Ovarian and Triple-Negative Breast Cancer: Efficacy, Safety, Pharmacokinetics and Germline BRCA Mutation Analysis
BMC MEDICINE（2023）
Key words
Ovarian cancer,Triple-negative breast cancer,PARP inhibitor,Anti-angiogenic therapy,gBRCA
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined